At the ESCMID Global 2025 conference, Bruker Corporation’s BRKR Microbiology and Infection Diagnostics division has announced the expansion of its microbiology solutions into Next-Generation ...

Barclays analyst Luke Sergott maintained a Buy rating on Bruker (BRKR – Research Report) today and set a price target of $50.00. The company’s ...

Bruker posts higher-than-expected Q1 revenue and announces NGS collaboration with Ridom to boost microbiology and infection ...

At the ESCMID Global 2025 conference, Bruker´s Microbiology and Infection Diagnostics division is announcing the expansion of ...

The company said, “This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage ...

Bruker expects first-quarter revenue to be $795 million to $800 million, ahead of Wall Street expectations. Analysts polled by FactSet are forecasting $758.4 million in quarterly revenue. The ...

Bruker Corporation’s BRKR share price has dipped by 11.48%, which has investors questioning if this is right time to buy.

Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's ...

Bruker Corporation BRKR has unveiled its breakthrough dissolution Dynamic Nuclear Polarization (d-DNP) Polarizer at the 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop ...

BILLERICA, Mass., April 11, 2025--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $ ...